| Citation: | Branch of Organ Transplantation of Chinese Medical Association. Technical specification for diagnosis and treatment of chronic renal allograft dysfunction (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(5): 526-532, 539. doi: 10.3969/j.issn.1674-7445.2019.05.011
|
| [1] |
CHAPMAN JR, O'CONNELL PJ, NANKIVELL BJ. Chronic renal allograft dysfunction[J]. J Am Soc Nephrol, 2005, 16(10):3015-3026. doi: 10.1681/ASN.2005050463
|
| [2] |
RIELLA LV, DJAMALI A, PASCUAL J. Chronic allograft injury: mechanisms and potential treatment targets[J]. Transplant Rev (Orlando), 2017, 31(1):1-9. DOI: 10.1016/j.trre.2016.10.005.
|
| [3] |
HARA S. Current pathological perspectives on chronic rejection in renal allografts[J]. Clin Exp Nephrol, 2017, 21(6):943-951. DOI: 10.1007/s10157-016-1361-x.
|
| [4] |
HAN SS, HUH W, PARK SK, et al. Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy[J]. Transpl Int, 2010, 23(2):169-175. DOI: 10.1111/j.1432-2277.2009.00966.x.
|
| [5] |
CRAVEDI P, KOPP JB, REMUZZI G. Recent progress in the pathophysiology and treatment of FSGS recurrence[J]. Am J Transplant, 2013, 13(2):266-274. DOI: 10.1111/ajt.12045.
|
| [6] |
QIN W, BECK LH JR, ZENG C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy[J]. J Am Soc Nephrol, 2011, 22(6):1137-1143. DOI: 10.1681/ASN.2010090967.
|
| [7] |
STAHL R, HOXHA E, FECHNER K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation[J]. N Engl J Med, 2010, 363(5):496-498. DOI: 10.1056/NEJMc1003066.
|
| [8] |
LARSEN CP, WALKER PD. Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy[J]. Transplantation, 2013, 95(10):1259-1262. DOI: 10.1097/TP.0b013e31828a947b.
|
| [9] |
PONTICELLI C, GLASSOCK RJ. De novo membranous nephropathy (MN) in kidney allografts. a peculiar form of alloimmune disease?[J]. Transpl Int, 2012, 25(12):1205-1210. DOI: 10.1111/j.1432-2277.2012.01548.x.
|
| [10] |
SETHI S, FERVENZA FC, ZHANG Y, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up[J]. Kidney Int, 2012, 82(4):465-473. doi: 10.1038/ki.2012.212
|
| [11] |
ZAND L, LORENZ EC, COSIO FG, et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation[J]. J Am Soc Nephrol, 2014, 25(5):1110-1117. DOI: 10.1681/ASN.2013070715.
|
| [12] |
文吉秋.移植肾C3肾小球病的诊治[J].中国实用内科杂志, 2017, 37(9): 794-797. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgsynkzz201709005
WEN JQ. Diagnosis and treatment of C3 glomerular disease in transplanted kidney[J]. Chin J Pract Intern Med, 2017, 37(9): 794-797. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgsynkzz201709005
|
| [13] |
文吉秋, 徐峰, 王维, 等.移植肾C3肾小球病3例临床病理特点及预后分析[J].中国实用内科杂志, 2017, 37(9): 90-94. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgsynkzz201709018
WEN JQ, XU F, WANG W, et al. Clinicopathologic features and prognosis of 3 cases of C3 glomerular disease in transplanted kidney[J]. Chin J Pract Intern Med, 2017, 37(9): 90-94. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgsynkzz201709018
|
| [14] |
MCCAUGHAN JA, O'ROURKE DM, COURTNEY AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies[J]. Am J Transplant, 2012, 12(4):1046-1051. DOI: 10.1111/j.1600-6143.2011.03923.x.
|
| [15] |
SAID SM, COSIO FG, VALERI AM, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft[J]. Kidney Int, 2018, 94(1):159-169. DOI: 10.1016/j.kint.2018.01.028.
|
| [16] |
WEN J, WANG W, XU F, et al. Clinicopathological analysis of proliferative glomerulonephritis with monoclonal IgG deposits in 5 renal allografts[J]. BMC Nephrol, 2018, 19(1):173. DOI: 10.1186/s12882-018-0969-3.
|
| [17] |
LARSEN CP, AMBUZS JM, BONSIB SM, et al. Membranous-like glomerulopathy with masked IgG kappa deposits[J]. Kidney Int, 2014, 86(1):154-161. DOI: 10.1038/ki.2013.548.
|
| [18] |
BUXEDA A, SAID SM, NASR SH, et al. Recurrent proliferative glomerulonephritis with monoclonal immunoglobulin deposits in kidney allografts treated with anti-CD20 antibodies[J]. Transplantation, 2019, 103(7):1477-1485. DOI: 10.1097/TP.0000000000002577.
|
| [19] |
NOTO R, KAMIURA N, ONO Y, et al. Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report[J]. BMC Nephrol, 2017, 18(1):127. DOI: 10.1186/s12882-017-0524-7.
|
| [20] |
STEGALL MD, CORNELL LD, PARK WD, et al. Renal allograft histology at 10 years after transplantation in the tacrolimus era: evidence of pervasive chronic injury[J]. Am J Transplant, 2018, 18(1):180-188. DOI: 10.1111/ajt.14431.
|
| [21] |
GASTON RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm[J]. Clin J Am Soc Nephrol, 2009, 4(12):2029-2034. DOI: 10.2215/CJN.03820609.
|
| [22] |
OJO AO, HELD PJ, PORT FK, et al. Chronic renal failure after transplantation of a nonrenal organ[J]. N Engl J Med, 2003, 349(10):931-940. doi: 10.1056/NEJMoa021744
|
| [23] |
PEREZ CP, PATEL N, MARDIS CR, et al. Belatacept in solid organ transplant: review of current literature across transplant types[J]. Transplantation, 2018, 102(9):1440-1452. DOI: 10.1097/TP.0000000000002291.
|
Figures(8) / Tables(2)
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad:
